Follow The Filings

COGT Cogent Biosciences

Cogent Biosciences earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 6 Nov EPS -0.55 — —
Rev — — —

Insider trades

Open-market buys and sales by COGT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All COGT insider trades
  • None no insider bought on the open market
  • $382M sold by 5 insiders outside a trading plan
  • $1.7M sold by 1 insider under 10b5-1 plans
  1. Arlene Morris Director
    Planned sale
    $1.7M 45,510 shares at $37.12 100% of stake
    Traded Aug 27 Filed Aug 31
  2. Fairmount Funds Management LLC Director
    Sale
    $243M 7,000,000 shares at $34.66 56% of stake
    Traded Mar 31 Filed Mar 31
  3. Fairmount Funds Management LLC Director
    Sale
    $127M 3,500,000 shares at $36.40 39% of stake
    Traded Jan 22 Filed Jan 22
  4. Evan Kearns Chief Legal Officer
    Sale
    $2.5M 65,000 shares at $38.70 37% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
  5. John L. Green CFO
    Sale
    $3M 77,000 shares at $38.68 37% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
  6. Jessica Sachs Chief Medical Officer
    Sale
    $3.2M 82,642 shares at $38.70 38% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025
  7. John Edward Robinson Chief Scientific Officer
    Sale
    $3.5M 90,000 shares at $38.74 39% of stake
    Traded Dec 26, 2025 Filed Dec 30, 2025

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 6 share withholdings for taxes, 2 gifts, 2 option exercises, and 1 conversion.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 1.01
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
424B5
8-K 8.01,9.01
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 5.07
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A
SCHEDULE 13D/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-K
SCHEDULE 13G/A —
SCHEDULE 13D/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.